Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

Pasireotide Acromegaly Study Group, S Petersenn, J Schopohl, A Barkan, P Mohideen, A Colao, R Abs, A Buchelt, Y-Y Ho, K Hu, Andrew Farrall, S Melmed, B M K Biller

Research output: Contribution to journalArticlepeer-review

Abstract

Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5). Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.
Original languageEnglish
Pages (from-to)2781-9
Number of pages9
JournalJournal of Clinical Endocrinology & Metabolism
Volume95
Issue number6
DOIs
Publication statusPublished - Jun 2010

Keywords

  • Acromegaly
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Glucose
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Endpoint Determination
  • Female
  • Human Growth Hormone
  • Humans
  • Insulin-Like Growth Factor I
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Octreotide
  • Pituitary Neoplasms
  • Somatostatin
  • Young Adult

Fingerprint

Dive into the research topics of 'Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial'. Together they form a unique fingerprint.

Cite this